Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.66
-0.36 (-2.76%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
434.93M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Sutro Biopharma | 99.61M |
| Prothena Corporation | 57.94M |
| Editas Medicine | 38.69M |
| Prelude Therapeutics | 16.72M |
| Evommune | 10.00M |
| Ovid Therapeutics | 7.12M |
| Artiva Biotherapeutics | 251.00K |
BNTC News
- 5 weeks ago - Guggenheim downgrades Benitec to Neutral, terminates coverage - TheFly
- 5 weeks ago - Benitec Biopharma downgraded to Neutral from Buy at Guggenheim - TheFly
- 2 months ago - Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Benitec Biopharma Earnings release: Q3 2026 - Filings
- 2 months ago - Benitec Biopharma Quarterly report: Q3 2026 - Filings
- 2 months ago - Benitec Biopharma initiated with an Outperform at Evercore ISI - TheFly
- 2 months ago - Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 4 months ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire